These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19034612)

  • 21. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report.
    Hatoum HA; Mahfouz RA; Otrock ZK; Hudaib AR; Taher AT; Shamseddine AI
    Am J Hematol; 2007 Jan; 82(1):69-72. PubMed ID: 16947317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA-DR antigen-negative acute myeloid leukemia.
    Wetzler M; McElwain BK; Stewart CC; Blumenson L; Mortazavi A; Ford LA; Slack JL; Barcos M; Ferrone S; Baer MR
    Leukemia; 2003 Apr; 17(4):707-15. PubMed ID: 12682628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
    Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
    [No Abstract]   [Full Text] [Related]  

  • 25. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Martínez-Cuadrón D; Boluda B; Martínez P; Bergua J; Rodríguez-Veiga R; Esteve J; Vives S; Serrano J; Vidriales B; Salamero O; Cordón L; Sempere A; Jiménez-Ubieto A; Prieto-Delgado J; Díaz-Beyá M; Garrido A; Benavente C; Pérez-Simón JA; Moscardó F; Sanz MA; Montesinos P;
    Ann Hematol; 2018 May; 97(5):763-772. PubMed ID: 29392425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of relapsed and refractory acute myeloid leukemia in adults.
    Lazzarino M; Morra E; Alessandrino EP; Merante S; Bernasconi P; Bonfichi M; Caldera D; Bernasconi C
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():121-3. PubMed ID: 2653487
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute myeloid leukaemia with abnormal eosinophil precursors without inversion 16.
    Rashidi A; Roullet MR
    Br J Haematol; 2012 Sep; 158(5):561. PubMed ID: 22758220
    [No Abstract]   [Full Text] [Related]  

  • 28. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
    Wiedower E; Jamy O; Martin MG
    Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
    Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
    Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
    Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
    Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myeloid leukemia with a novel CPSF6-RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy.
    Zhang Z; Jiang M; Borthakur G; Luan S; Huang X; Tang G; Xu Q; Ji D; Boyer AD; Li F; Huang R; You MJ
    Am J Hematol; 2020 Feb; 95(2):E48-E51. PubMed ID: 31769058
    [No Abstract]   [Full Text] [Related]  

  • 32. Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
    Shen Y; Chen J; Liu Y; Wu D
    Chemotherapy; 2014; 60(5-6):368-74. PubMed ID: 26496511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
    Vogler WR; Velez-Garcia E; Omura G; Raney M
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
    [No Abstract]   [Full Text] [Related]  

  • 34. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
    Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
    Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Estey EH; Kantarjian H; Keating M
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
    Minetto P; Guolo F; Clavio M; Kunkl A; Colombo N; Carminati E; Fugazza G; Matarese S; Guardo D; Ballerini F; Di Grazia C; Raiola AM; Cagnetta A; Cea M; Miglino M; Lemoli RM; Gobbi M
    Br J Haematol; 2019 Feb; 184(3):457-460. PubMed ID: 29359798
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
    Seligson ND; Hobbs ALV; Leonard JM; Mills EL; Evans AG; Goorha S
    Ann Pharmacother; 2018 May; 52(5):439-445. PubMed ID: 29241342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.
    Bolaños-Meade J; Karp JE; Guo C; Sarkodee-Adoo CB; Rapoport AP; Tidwell ML; Buddharaju LN; Chen TT
    Leuk Res; 2003 Apr; 27(4):313-21. PubMed ID: 12531222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLAI induction regimen in elderly patients with acute myeloid leukemia.
    Cerrano M; Candoni A; Crisà E; Dubbini MV; D'Ardia S; Zannier ME; Boccadoro M; Audisio E; Bruno B; Ferrero D
    Leuk Lymphoma; 2019 Dec; 60(13):3339-3340. PubMed ID: 31159609
    [No Abstract]   [Full Text] [Related]  

  • 40. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.
    Kadia T; Kantarjian H; Garcia-Manero G; Borthakur G; Wang X; Patel K; Jabbour E; Brandt M; Daver N; Pemmaraju N; Pierce S; Cortes J; Ravandi F
    Br J Haematol; 2015 Aug; 170(4):590-3. PubMed ID: 25716073
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.